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Abstract
Background: Dengue fever, a mosquito-borne disease, is associated with illness of varying severity in countries in
the tropics and sub tropics. Dengue cases continue to be detected more frequently and its geographic range
continues to expand. We report the largest documented laboratory confirmed circulation of dengue virus in parts
of Kenya since 1982.
Methods: From September 2011 to December 2014, 868 samples from febrile patients were received from
hospitals in Nairobi, northern and coastal Kenya. The immunoglobulin M enzyme linked immunosorbent assay
(IgM ELISA) was used to test for the presence of IgM antibodies against dengue, yellow fever, West Nile and Zika.
Reverse transcription polymerase chain reaction (RT-PCR) utilizing flavivirus family, yellow fever, West Nile,
consensus and sero type dengue primers were used to detect acute arbovirus infections and determine the
infecting serotypes. Representative samples of PCR positive samples for each of the three dengue serotypes
detected were sequenced to confirm circulation of the various dengue serotypes.
Results: Forty percent (345/868) of the samples tested positive for dengue by either IgM ELISA (14.6 %) or by
RT-PCR (25.1 %). Three dengue serotypes 1–3 (DENV1-3) were detected by serotype specific RT-PCR and sequencing
with their numbers varying from year to year and by region. The overall predominant serotype detected from
2011–2014 was DENV1 accounting for 44 % (96/218) of all the serotypes detected, followed by DENV2 accounting
for 38.5 % (84/218) and then DENV3 which accounted for 17.4 % (38/218). Yellow fever, West Nile and Zika was not
detected in any of the samples tested.
Conclusion: From 2011–2014 serotypes 1, 2 and 3 were detected in the Northern and Coastal parts of Kenya.
This confirmed the occurrence of cases and active circulation of dengue in parts of Kenya. These results have
documented three circulating serotypes and highlight the need for the establishment of active dengue
surveillance to continuously detect cases, circulating serotypes, and determine dengue fever disease burden in
the country and region.
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Background
Dengue fever is regarded as the most important re-
emerging mosquito-borne disease globally and is en-
demic in more than 125 countries worldwide [1]. It is an
acute systemic viral illness that manifests with varying
degrees of severity ranging from a mild febrile illness to
severe hemorrhagic presentations, dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS). Dengue
viruses are mosquito-borne members of the Flavivirus
genus, family Flaviviridae, first isolated in 1943 and
1945 in Japan and Hawaii respectively [2]. Dengue fever
is caused by infection with one of four distinct dengue
serotypes (DENV1 to DENV4) that are genetically re-
lated but antigenically distinct and with extensive genetic
diversity within the different serotypes. Immunity is
serotype specific and there is no cross protection be-
tween the serotypes [3]. It is estimated that 96 million
apparent dengue infections occurred worldwide in 2010
with most of these being reported in Asia, which bore
70 % of the global burden while Africa bore 16 % of the
global burden. There are more than 390 million cases
annually, of which 294 million maybe in apparent infec-
tions not detected by the public health system [4].
In existence for centuries, the Chinese documented
symptoms compatible with dengue in 992 AD and asso-
ciated the disease with flying insects and water [5]. It
was not until the 20th century when the viral etiology
and the role of mosquitoes in its transmission were de-
termined [1]. Aedes aegypti (A. aegypti), the main
arthropod vector for dengue has its origins in Africa and
is wide spread in Africa and the tropics. The mosquito
has a high affinity for human blood, a high adaptation to
urban dwelling in close proximity to human settlements,
and a high vectorial capacity for the four dengue sero-
types [6]. Rapid urbanization and globalization is associ-
ated with the expansion of dengue fever in the 20th
century [7]. It breeds in and around houses in regular
water containers or disposed water-holding vessels. Due
to its limited flight range the female A. aegypti persists
in a domesticated environment contributing to the
spread of dengue through high human-mosquito-human
contact within communities [8].
The first documented dengue outbreak in Africa oc-
curred in Durban, South Africa in 1927 as determined
by a retrospective serological study [9]. Subsequently,
dengue virus isolations in Africa have been reported in
1964–68 in Nigeria (DENV1 and 2) [10], in 1983–85 in
Mozambique (DENV3) [11], in 1984 in Sudan (DENV1
and 2) [12] and in 1986 in Senegal (DENV4) [13]. In the
past five decades sporadic or epidemic cases of dengue
have been increasing in sub-Saharan Africa with 22
countries reporting outbreaks. East Africa has experi-
enced the largest burden in this period with outbreaks
occurring in the Island nations of Réunion (1977–1978),
the Seychelles (1977–1979), the Comoros (1992–1993),
and Cape Verde (2009). In addition Djibouti also re-
corded a large outbreak in 1992–1993. Approximately
300,000 cases were detected in these 5 outbreaks. Dengue
is currently endemic in 34 African countries with trans-
mission being reported through local disease transmission,
detection of laboratory confirmed cases, and detection
among travelers returning to countries not endemic to
dengue [14].
In Kenya, the first documented dengue outbreak
(DENV2) occurred in 1982 in the coastal cities of Malindi
and Mombasa and was thought to have spread from an
outbreak that had occurred in the Seychelles in 1979–
1980 [15]. Subsequently, although dengue outbreaks were
documented in the neighboring countries of Somalia,
Djibouti and South Sudan [14, 16], only rare sporadic
cases of DENV2 were detected in the coastal town of
Mombasa. Seroprevalence studies performed in Kenya
have indicated high prevalence of dengue in coastal
Malindi at 34.17 % and lower prevalence in western
Busia at 1.96 % [17]. Due to lack of active surveillance
and reporting structures for dengue infections in much
of East Africa, there is a lack of appreciation of the burden
of the disease in the region and detection of cases is often
hampered by non-specific clinical manifestation of the ill-
ness, which mimics other common fever causing illnesses
like malaria and typhoid fever and the unavailability of
diagnostic capabilities in most of the health centers.
In the continued absence of a viable/approved vaccine,
the prevention and control of dengue is currently reliant
on vector control methods and early detection of cases
through continued surveillance that trigger mosquito
control activities to alleviate human suffering and
emergence of severe disease caused by widespread
virus transmission of multiple serotypes.
In September 2011, reports of increased cases of acute
febrile illness were reported in Mandera in northeastern
Kenya bordering Somalia. In the subsequent months and
years, the viral hemorrhagic fever (VHF) laboratory at
the Kenya Medical Research Institute (KEMRI) continued
to receive samples from northeastern Kenya and from
Mombasa on the Kenya coast for dengue fever testing.
Laboratory testing was conducted with the support of the
Global Emerging Infections Surveillance (GEIS) program of
the United States Army Medical Research Directorate
Kenya (USAMRD-K). The laboratory responds to reports
of suspected arbovirus/VHF infections in Kenya and on re-
quest of the World Health Organization (WHO) other
countries neighboring Kenya that lack laboratory capacity
by performing diagnostic testing on samples of suspected
cases of arboviruses and VHF infections. From September
2011 to December 2014, as part of the Kenya Ministry of
Health response effort, the laboratory received samples
from diverse private and government health facilities in
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northeastern Kenya in Mandera and Wajir counties, hospi-
tals in the capital city of Nairobi and from both private and
government hospitals in Mombasa, Malindi and Lamu
along the Kenyan coast (Fig. 1).
Methods
Study population and sample collection
Samples were collected from patients of both sexes and
all ages who presented with a sudden onset of fever ac-
companied by body aches. Following the detection of
initial dengue cases a clinical working case definition
was developed by the Division of Disease Surveillance
and Response, Ministry of Health and sent out to all
health facilities in the affected and high risk areas.
Sample collection and testing
Venous blood was collected in vacutainer tubes with no
anticoagulant using standard phlebotomy practices from
patients that met the case definition. Samples were
transported to the laboratory in cold storage where they
were centrifuged and serum obtained for testing. All
samples were tested using the IgM antibody capture
enzyme-linked immunosorbent assay (MAC-ELISA) to
detect IgM antibodies against dengue, yellow Fever and
West Nile. A subset of the samples was tested for expos-
ure to Zika using a commercial IgM kit. Flavivirus family,
yellow fever, West Nile, dengue consensus and dengue
serotype specific RT-PCR primers were used to detect
an acute infection and to determine the infecting sero-
type. Representative samples of RT-PCR positive sam-
ples for each of the three dengue serotypes detected
were sequenced to confirm circulation of the various
dengue serotypes.
Laboratory analysis
MAC-enzyme linked immunosorbent assay
The IgM antibody capture ELISA (MAC-ELISA) used to
detect presence of IgM antibodies was a laboratory
derived test (LDT) provided by the Diagnostic Systems
Division, United States Army Medical Research Institute
of Infectious Diseases (USAMRIID). A 96 well Immuno-
lon plate (Nunc, Denmark) was coated with a commer-
cial anti-human IgM antibody that reacts specifically
with human IgM, (goat anti-human IgM, Kirkegaard and
Perry laboratories Gaithersburg, MD, USA) and incu-
bated at +4 °C for 12–16 h. The plate was washed using
a wash buffer (PBS, pH 7.4, 0.01 Merthiolate, 0.1
Tween-20). This was followed by addition of the dengue
Fig. 1 Map of Kenya showing locations from which dengue cases were detected, 2011–2014. Map of Kenya showing the regions and number of
samples received from different parts of Kenya. Samples were received from 7 regions of Kenya and from neighboring Somalia. Dengue serotypes
1–3 represented in different colours in the map were detected in various regions as shown in the pie charts. Only sites from which dengue cases
were detected are shown on this map
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IgM positive control, negative control and sample all
diluted 1:100 in diluent buffer (PBS, pH 7.4, 0.01 Mer-
thiolate, 0.1 Tween-20, 5 % skim milk). Plates were
incubated at 37 °C for one hour. The plate was then
washed and 100 μl of dengue antigen solution consisting
of equal amounts of inactivated lyophilized dengue fever
virus 1–4 added in one half of the test wells and a corre-
sponding negative antigen (same dilution) is added in
the other half of the test wells.
Dengue antigens used in the assay were obtained from
various sources. Dengue 1 - Hawaii isolated in 1944
from a human [18], dengue 2 - New Guinea C, isolated
in 1944 from a human [19] dengue 3 - H87, Philippines
isolated in 1956 from a human and dengue 4 - H241,
Philippines isolated in 1956 from a human [20]. The
IgM antigens were supernatants from vero cells infected
with the appropriate isolate and supernatants were inac-
tivated using 0.3 % beta-propiolactone and cobalt irradi-
ated using 3 million rads and safety tested. The plate
was incubated for one hour at 37 °C. After washing
100 μl dengue specific detector antibodies (anti-dengue
hyperimmune mouse ascitic fluid) was added to each
well and incubated for one hour at 37 °C. The plate was
washed and 100 μl of HRP labelled goat anti-mouse IgG,
heavy and light chain specific conjugate that reacts spe-
cifically with mouse IgG (Kirkergard and Perry, catalog
074–1806) added in all the wells and plate incubated for
one hour at 37 °C. The plate was then washed and
100 μl of ABTS substrate (Kirkergard and Perry, Cat.
No. N8 50-62-00, Gaithersburg, MD) was added and the
plate incubated at 37 °C for 30 min. The reaction was
visualized by a green colour and the optical density (OD
value) was read with a spectrophotometer at 405 nm.
The adjusted OD was calculated by subtracting the OD
of the negative/mock antigen coated wells from the posi-
tive antigen coated wells. The OD cut-off was calculated
as the mean of the adjusted OD of the negative control
sera plus three times the standard deviations. All sam-
ples were also tested for IgM antibodies against West
Nile and yellow fever using the same procedure as out-
lined for dengue above but with variations in the positive
controls, the positive and mock antigens and the virus
specific detector antibodies. The yellow fever antigen
used was obtained from the Asibi strain isolated from a
human in Ghana in 1927 [21] while the West Nile anti-
gen was the Eg101 strain isolated in Egypt in 1951 [22].
To rule out cross reactivity with Zika, 15 randomly
picked samples that tested positive for dengue IgM anti-
bodies were screened using the Euroimmun Anti-Zika
virus IgM ELISA (Euroimmun, Lübeck, Germany) kit
following the manufacturer’s instructions. Briefly the
serum was diluted 1:101 in sample buffer, incubated at
room temperature for 10 min, added into the appropri-
ate microplate wells and incubated at 37 °C for 1 h. This
was followed by addition of a peroxidase labelled anti
human IgM conjugate, substrate, and finally a stop solu-
tion while performing the wash steps in between incuba-
tions and adhering to the appropriate incubation
temperatures for each step. The optical density (OD)
was measured using an ELx800™ absorbance microplate
reader (Biotek Winooski, Vermont, USA). A cut-off ratio
was calculated, and values <0.8 were regarded as nega-
tive, ≥0.8 to <1.1 as borderline, and ≥ 1.1 as positive [23].
Nucleic acid (RNA) extraction
Viral RNA was extracted using the QIAamp Viral RNA
Minikit (QIAGEN, Hilden Germany) according to the
manufacture’s protocol. A final volume of 60 μL of RNA
was obtained and used as a template for cDNA synthesis
and for the subsequent PCR reactions.
cDNA synthesis from viral RNA
To convert extracted RNA to cDNA, 10 μL of the ex-
tracted sample viral RNA was mixed with 2 μL of 50 ng/
μL random hexamer primer in a 0.2 ml PCR tube. The
mixture was incubated in a thermocycler for 10 min at
70 °C. The reaction was stopped and the following compo-
nents added to the PCR tube: 4 μL of 5X First Strand Buf-
fer (Invitrogen), 1 μl of 10 mM dNTPs, 2 μl of 100 mM
DTT, 0.25 μl of RNAse Inhibitor (40U/μl) and 1 μl of
Superscript III Reverse transcriptase (200 U/μl). The mix-
ture was then placed in a thermocycler set at the following
conditions: 25 °C for 15 min, 50 °C for 50 min, followed
by 70 °C for 15 min in the thermocycler and 4 °C hold
temperature. A total of 20 μL of cDNA was obtained.
The PCR amplification of targeted viral sequences in
the cDNA was performed in a 25-μL reaction containing:
12.5 μl of Amplitaq Gold 360 PCR master mix (Applied
Biosystems USA), 50 picomoles each of forward and re-
verse primer, 2 μl of the cDNA and 9.5 μl of DEPC treated
water to top up to 25 μl. Samples were first tested using
flavivirus family primers. Samples testing positive with fla-
vivirus family primers were further tested with yellow
fever, West Nile and consensus dengue primers D1 and
D2. Samples testing positive with the dengue consensus
primers that target the E/NS1 junction of the virus
genome were further tested for the 4 dengue sero types
using the appropriate primers (Table 1).
The primer sequences above were used to detect ex-
posure to the various arboviruses using amplification
conditions as described in the corresponding references
for each primer listed.
A positive control cDNA and a negative control were
included during the setting up of all PCR reactions. Elec-
trophoresis of the amplified DNA products was done on
a 1–2 % agarose gel in 1 % Tris-borate EDTA buffer
stained with ethidium bromide. The PCR product bands
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were visualized by a UV trans illuminator and recorded
using a gel photo imaging system.
Sequencing and phylogenetic analysis
Amplified target DNA bands were either purified directly
from the PCR reaction or from the gel using Wizard® SV
Gel and PCR Clean-Up System kit (Promega Madison,
WI, USA). Sequencing was outsourced and performed
using ABI-PRISM 3130 Genetic Analyzer (Applied Bio-
systems, Foster City, CA). Both forward and reverse
strands were sequenced and the raw chromatogram file
was edited for bad calls using DNAbaser v.3.0.The se-
quences were compared with available sequences using
Basic Local Alignment Search Tool and the GenBank
database to confirm the identity of the virus isolate.
The sequences were aligned using Muscle [24] in
Molecular Evolutionary Genetics Analysis (MEGA)
software version 76 was used for phylogenetic analysis
using the Maximum likelihood statistical method tested
with 1000 bootstrap replicates based on the Tamura-
Nei model [25]. The phylogenetic tree was inferred in
MEGA version 7. A total of 15 (5 for each serotype
DENV1-3) samples were sequenced.
Results
From July 2011 to December 2014 a total of 868 clinical
samples obtained from febrile cases were tested. The
least number of samples were received in 2012 (32/868)
while the year 2013 accounted for the highest number of
samples received (567/868).
Out of the 868, 40 % (345/868) of the samples were
positive for dengue; 14.6 % (127/868) were positive for
dengue IgM antibodies while 25.1 % (218/868) were
positive for various dengue serotypes by RT-PCR
(Table 2).
A total of 868 samples were tested in the 4 year period
and numbers of dengue positives and serotypes detected
varied in the different years.
Of the 345 samples that tested positive for dengue 6 %
(21/345) tested positive for dengue by both IgM ELISA
and RT-PCR.
Overall, 68 % (588/868) of samples were from male
patients and 32 % (280/868) were from female patients).
The 21–50 year age group accounted for 52 % (454/868)
of all the samples received and 49.8 % (172/345) of all
dengue positive cases detected.
Three dengue serotypes were detected during this
period (DENV1-3) with no case of DENV4 being de-
tected. Serotypes detected varied by year and region with
DENV1 accounting for 44 % (96/218) of the three sero-
types detected followed by DENV2 at 38.5 % (84/218)
and DENV3 17.% (38/218) detected in both the northern
and coastal regions of Kenya (Fig. 2).
Samples from the coast predominantly tested positive
for DENV1 (88/160) followed by DENV 2 (69/160) with
the two serotypes accounting for 98 % of all the sero-
types from the coast. In northeastern Kenya, DENV 3
was dominant accounting for 72 % (28/39) of all the
DENV serotypes detected during this reporting period in
the region (Fig. 2).
In 2011, 129 samples were received from six facilities
with most of the samples coming between September
and November from northeastern region and Nairobi
accounting for 15 % (129/868) of all the samples tested
2011 to 2014. Overall, 46.5 % (60/129) of samples received
Table 1 Primer sequences used for flavivirus, yellow fever, West Nile, dengue consensus and sero type specific RT-PCR reactions
Primer Sequence Base pair size of amplified product Reference
FU1
CFD3
5′- TAC AAC ATG ATG GGA AAG AGA GAG AA-3′




5′-GCA GAG TGA TCG ACA GCC G-3′
5′-CCA CCA GAC CAT TCG GCA TG-3′
258 West Nile [47]
YF7 R
CAGF
5′- AAT GCT CCC TTT CCC AAA TA- 3′
5′- CGA GTT GCT AGG CAA TAA ACA CAT TTG GA-3





511 Dengue consensus [49]
TS1 5′-CGTCTCAGTGATCCGGGGG-3′ 482 (Dl and TS1) DENV1 [49]
TS2 5′-CGCCACAAGGGCCATGAACAG-3′ 119 (Dl and TS2) DENV2 [49]
TS3 5′-TAACATCATCATGAGACAGAGC-3′ 290 (Dl and TS3) DENV3 [49]
TS4 5′-CTCTGTTGTCTTAAACAAGAGA-3′ 392 (Dl and TS4) DENV4 [49]
Table 2 Number of dengue positives cases detected in Kenya;
2011-2014
Numbers detected
Year DENV1 DENV2 DENV3 Den IgM Negative
2011 6 3 32 19 69
2012 0 9 2 6 15
2013 89 60 4 70 344
2014 1 12 0 32 95
Total 96 84 38 127 523
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were positive for dengue; 32 % (41/129) were positive by
RT-PCR and 15 % (19/129) were positive by MAC ELISA.
DENV3, DENV1 and DENV2 accounted for 78 % (32/41),
15 % (6/41) and 7 % (3/41) of all the PCR positive samples,
respectively. A subset of 34 samples was received from
Somalia in July 2011 of which 44 % (15/34) tested positive
for DENV1-3 and IgM antibodies (Fig. 2).
In 2012 there was a drop in the number of samples
received. Only 32 samples were received from three
facilities mostly between February and April from north-
eastern region. It is not clear what factors were
associated with the sudden reduced numbers of samples
received at the laboratory. We speculate that it may not
have been associated with a sudden drop in patients with
fever but more due to the public health response mea-
sures following the detection of cases in 2011. Detection
of cases in 2011 was followed by dispatch of response
teams tasked with initiating community sensitization on
infection prevention, mosquito control activities and
supplied local health clinics with rapid dengue diagnostic
kits hence samples were tested at the respective sites.
The samples accounted for 4 % (32/868) of the total
samples received and 53 % (17/32) tested positive for
dengue; 34 % (11/32) were positive by RT-PCR with
DENV2 accounting for 82 % (9/11) and DENV3 ac-
counting for 18 % (2/11) of the PCR positives (Fig. 2).
In 2013, a total of 567 samples were received from
seven facilities, with most coming between April and
May accounting for 65 % of all the samples received.
The majority of samples came from Mombasa ac-
counting for 89 % (507/567) of all samples received
that year and 57 % (507/864) of all the samples re-
ceived over the four year study. The remaining samples
came from northeastern Kenya. Overall, 39.3 % (223/567)
of the samples were positive for dengue by either RT-PCR
or IgM ELISA. DENV1 and DENV2 accounted for 39.9 %
(89/223) and 26.9 % (60/223) of the positive cases, res-
pectively. DENV3 was detected in 1.7 % (4/223) of the
positive cases (Fig. 2).
In 2014, a total of 140 samples from seven facilities
were received mostly from the coast of which 32 % (45/
140) tested positive for dengue; 71 % (32/45) were
detected by IgM ELISA and DENV2 and DENV1
accounted for 26.6 % (12/45) and 2.2 % (1/45) of the
PCR positive samples, respectively (Fig. 2).
All positive patient samples collected from Nairobi
had a travel history to either the northern, eastern, or
coastal parts of Kenya where active transmission was
ongoing during the surveillance period. DENV1-3 was
detected in Nairobi during this period, but there was
no evidence of active transmission documented.
Co-infection with more than one serotype was detected
in two samples. Co-infection with DENV2 and 3 was de-
tected in one sample collected in Mandera in the early
stages of the outbreak in 2011 and the second in a sample
from Mombasa that also had both DENV2 and 3 in 2013.
Co infections with other flaviviruses (yellow fever and
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Fig. 2 Number of dengue cases per region in Kenya, 2011–2014. Distribution of DENV serotypes in various regions in Kenya varied from 2011
to 2014. Overall, DENV1 was the most dominant serotype followed by DENV2 and 3 respectively. The colour green, purple, blue and orange
represent the number of DENV-1, DENV-2, DENV-3 and IgM cases detected respectively
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samples tested. The IgM assays performed did not detect
yellow fever, West Nile and Zika in the samples tested.
Of the 15 samples sequenced, 12 samples gave good
quality reads and 5 were able to sequence the full 511
base pair region containing capsid and pre M genes. The
remaining seven had good quality sequences for the
capsid gene. The 12 sequences were trimmed to remain
with capsid gene which was used for phylogenetic ana-
lysis. Phylogenetic analysis of the capsid gene sequences
for representative selected PCR positive samples from
the cases revealed that DENV1 isolates from Mombasa
(2013) showed close relatedness to a DENV1 isolate
from Djibouti isolated in 1998. All the DENV2 isolates
from Kenya detected in Mombasa in 2013 showed close
relatedness to isolates detected in different parts of Asia.
All DENV3 isolates, two from Mandera (2011), two from
Mombasa (2013) and one from Wajir (2014) were
closely related to a DENV3 isolates from Pakistan, China
and India obtained in the year 2006, 2013 and 2009,
respectively (Fig. 3).
Discussion
Although considered endemic in Africa and Kenya [14],
there has been limited information documenting active
dengue virus transmission in Kenya among the human
population since the early 1980s. Current available infor-
mation has relied on serological surveys [17] and has
not described the circulating serotypes in the country.
Fig. 3 Maximum Likelihood tree of Dengue virus capsid sequences. Phylogenetic relationships of Kenyan isolates of DENV-1, DENV-2 and DENV-3
as inferred by using the Maximum Likelihood method based on the Tamura-Nei model. The percentage of trees in which the associated taxa
clustered together is shown next to the branches. Bootstrap values above 80 % are highlighted. The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site. The analysis involved 34 nucleotide sequences. There were a total of 200 positions in the final
dataset. Evolutionary analyses were conducted in MEGA7
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With 50 % of the world’s population living in dengue
endemic countries, Africa included; the continent con-
tinues to face challenges in case detection and reporting
resulting in limited information available towards under-
standing the true disease burden and economic impact
of dengue. Lack of awareness of dengue among health
workers, erratic treatment seeking behavior among pop-
ulations, presence of symptomatically similar illnesses
like malaria and typhoid, low case fatality rates, limited
availability appropriate diagnostic systems, and under
reporting by existing public health systems all contribute
to under recognition of dengue in the continent [1, 26].
Results during this 4 year period were able to detect
multiple dengue serotypes and helped to provide clear
evidence of active dengue transmission and identified
serotypes circulating in parts of northeastern and
coastal Kenya.
All four dengue serotypes have been detected in Africa
[14]. Our laboratory based results showed that in parts
of Kenya DENV1 and 2 were most dominant. This is
consistent with literature suggesting most epidemics in
Africa are caused by serotypes 1 and 2 [14, 16]. Infection
with DENV4 is less common, but it has been documented
in parts of Africa [13] and in Europe from travelers
returning from Africa [27]. DENV4 was not detected in
any of the 868 cases tested in this period. It is unclear why
DENV4 was not in circulation. Since the serotype is asso-
ciated with mild clinical disease, the absence of complica-
tions may have resulted in patients not seeking treatment;
hence it would often go undetected where it occurs [28].
Detection of the first dengue cases in northeastern
Kenya in September 2011 was preceded by dengue de-
tection in samples from Mogadishu, Somalia in February
2011, which suggested there was active transmission of
dengue going on in Somalia. From the Somali samples,
three serotypes (DENV1-3) were detected. In the Kenya
2011 cases, only DENV3 was detected in samples from
Mandera in northeastern Kenya. By 2013, DENV1-3 was
being detected in samples from the northern part of
Kenya. It is reasonable that the cases in Mandera on the
border with Somalia may have resulted from infected
travelers from Somalia.
Kenya and Somalia share a long porous border where
communities freely interact in search of pasture and
other economic activities. Though it may be assumed
that the infection spread from Somalia into Kenya, it is
not clear why there was a six month gap between the
Somali cases and the first detection in northeastern
Kenya. It may be that the first cases went undetected or
were misdiagnosed as malaria. Considering that no se-
vere dengue infections were detected in Kenya and that
the infections are self-limiting, the initial cases may have
resolved only to be detected much later when it affected
large populations concentrated in the major town of
Mandera. All the three serotypes detected in Somalia
were also detected in northeastern Kenya. Somalia is
currently hosting peace keeping forces from various
parts of the world. The forces present a naïve population
and several outbreaks among peace keeping forces have
been documented [29]. Cross border dengue infections
is of concern among many countries since it is considered
a major source of dengue spread [30].
Urbanization and infrastructure connectivity has been
shown to be a major factor facilitating the spread of
dengue infections between affected and non-affected
areas [6]. Mandera is home to the Kenya Somali ethnic
community who practice pastoral farming, but live in
urban setting in Mandera town. The town lacks piped
water, relying on water collected from a nearby river or
occasional rainfall. The water is stored in large concrete
water cisterns and other artificial containers that are per-
fect breeding sites for Aedes aegypti, the primary vector
of dengue viruses.
Since the first detection of dengue in 1982, coastal
Kenya has long been suspected of being a dengue en-
demic zone. Numerous studies have attempted to show
dengue circulation in human and vector populations and
the presence of competent vectors [17, 31]. This study
documented the circulation of multiple dengue serotypes
(DENV1-3) in Kenya and has confirmed the presence of
ongoing virus transmission.
Dengue fever cases were identified in Nairobi, the
capital city of Kenya, however all cases had a prior his-
tory of recent travel to the dengue affected areas of
northeastern and coastal Kenya. Despite detection of
acute cases in Nairobi, there was no evidence of active
dengue transmission. It is not clear why this was so, but
we speculate that the numbers of acute cases (eight) could
have been too few and spread apart for the establishment
of active local transmission. In addition, possible inherent
differences in the vector competence capabilities to
dengue virus of the Nairobi Ae. aegypti mosquito popula-
tion compared to populations in other regions with active
cases coupled with other environmental factors may have
played a role in the lack of establishment of potential
active transmission [31].
No case of DHF/DSS was detected during the surveil-
lance period despite the co-circulation of multiple sero-
types (DENV1-3), a phenomenon commonly associated
with DHF/DSS. The primary infecting serotype deter-
mines severity of the infection. Primary infections with
DENV1 and 3 tend to cause more severe clinical disease
manifestations, while DENV2 and 4 are associated with
increased severity when they occur as secondary infec-
tions [32] Co-infection with more than one serotype was
detected in two samples. Co-infection with DENV2 and
3 was detected in a sample collected in Mandera in the
early stages of the outbreak in 2011 and a sample from
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Mombasa with co-infection of DENV2 and 3 was
detected in 2013. Due to logistical constraints, the la-
boratory was not able to ascertain the outcome on these
patients. Previous studies have also shown that race may
also play a role in offering partial protection against se-
vere forms of dengue. Genetic polymorphisms that offer
partial protection against severe forms of dengue have
been identified in people of African descent [33, 34].
This could have played a role, but cannot be substanti-
ated from laboratory based surveillance.
Clinical outcomes of dengue cases may be influenced
by the circulation of multiple DENV serotypes and is
considered a factor in the reemergence of dengue
hemorrhagic fever [35]. Co-circulation of various DENV
serotypes is well documented as a frequent occurrence
in various parts of the world. The outbreak in Kenya
was characterized by the detection of multiple serotypes
with the predominant serotype being DENV1, followed
by DENV2 and then DENV3, which is similar to most
dengue outbreaks detected globally where multiple sero-
types are detected [36, 37].
The detection of multiple dengue serotypes in Kenya
with close relatedness to isolates obtained in other parts
of Africa, South and South East Asia shows the continued
movement and the wide geographic range of the dengue
serotypes. Only DENV1 isolates showed any close related-
ness to an African isolate from Djibouti (AF298808),
which has been shown to be more genetically related to
Asian isolates than to African isolates [38]. All DENV2
and 3 isolates showed relatedness to Asian isolates indi-
cating transmission and sustenance in countries away
from the initial geographic origin.
Over the last decade, Kenya has developed into a
major air and sea port transport hub in the region con-
necting the Asian and African continents for commercial
and tourist purposes. Increased travel between affected
and non-affected areas constitutes a constant threat with
travelers acting as vehicles of disease spread. In addition
rapid urbanization and globalization is associated with the
expansion of dengue transmission by providing a condu-
cive environment for the mosquito vector [39, 40].
Of concern were the 60 % of the samples that tested
negative for dengue, West Nile and yellow fever viruses
by IgM ELISA and RT-PCR despite being collected from
patients presenting with fever. This demonstrates the
need to constantly review and avail comprehensive
differential disease diagnostic panels at health facilities
where possible and at the testing laboratories. This will
enhance detection of underlying or co circulating ree-
merging and emerging disease threats caused by para-
sitic, viral, bacterial or other pathogens associated
with febrile illness manifestations in human popula-
tions. An opportunity to determine the etiology of
arbovirus infections is often missed as fevers caused
by arboviruses may be misdiagnosed as malaria or Vis
versa. In addition, overlaps in geographical locations
and concurrent infections of arboviruses from the
same or different families are well documented in
various parts of the world and Africa [40–45]. This
highlights the need for continued vigilance and review
of the existing testing algorithms for diseases associ-
ated with febrile manifestations.
In this reporting period, we were only able to screen a
small subset of samples (12 % of the dengue IgM posi-
tives) for cross reactivity with Zika for logistical reasons.
Although all the samples tested negative for Zika IgM
antibodies, our results may be biased towards dengue as
we were not able to screen for Zika in all the samples
that tested positive for dengue IgM antibodies.
As dengue becomes endemic in Kenya, health care
providers are increasingly aware of the need to quickly
detect infection and provide appropriate care to patients.
The availability of rapid diagnostic kits at health facilities
has resulted in the reduced flow of samples to the
KEMRI laboratory, but cases continue to be detected in
the northern and coastal regions of Kenya.
Conclusion
Confirmatory laboratory diagnosis in Kenya facilitated
the detection of dengue virus circulation in the northern
and coastal regions of Kenya and in the capital city
Nairobi. Early laboratory detection allows clinicians to
institute supportive treatment for better prognosis.
There is need to establish on-going dengue surveillance
to continuously detect outbreaks, the serotypes circulating,
and determine dengue fever disease burden in the region.
Seasonal variation should also be established to identify
high risk times and facilitate appropriate public health
responses. Circulation of multiple serotypes may also lead
to increased cases of severe form of dengue.
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